- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Terrill Jordan Discusses Making Refinements in Year 2 of OCM
Year 2 of the Oncology Care Model is about learning from the lessons of year 1 and extending implementation that has already been started, said Terrill Jordan, CEO of Regional Cancer Care Associates.
Year 2 of the Oncology Care Model (OCM) is about learning from the lessons of year 1 and extending implementation that has already been started, said Terrill Jordan, CEO of Regional Cancer Care Associates.
Transcript
In terms of next steps, what does year 2 of OCM hold for you?
Year 2 is about extending the implementation that we’ve already started. So we’ve learned a lot over that year. We learned to prioritize a little bit more in terms of the data we need and how we prioritize the data as we deliver it to our clinicians. The education process, we’ve learned a little bit more about how we should structure the education process for our clinicians. So we’ve worked a lot on that. We’re looking at the workflow and how we can handle the workflow a little bit differently. We get the feedback now, the feedback loop is taking place. We’re learning what we didn’t do so well, we are learning what worked.
And our clinicians, I think, are a big change, our clinicians are engaging now in a way that they didn’t engage at the start. While they were intellectually engaged, they weren’t emotionally engaged. Now we are seeing emotional engagement. It’s that refining process that is starting to take place.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
